William J. McCarty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William J. McCarty has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Robert L. Sah
Shu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, California, USA
7 shared publications - Osman Berk Usta
Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
6 shared publications Inna Golberg
Center for Engineering in Medicine at Massachusetts General Hospital, Harvard Medical School and Shriners Hospital for Children, 51 Blossom St., Boston, 02144, Massachusetts
5 shared publications- Manjunath Hegde
Cancer Sciences, Faculty of Medicine, University of Southampton, UK
5 shared publications - Martin L. Yarmush
Department of Biomedical Engineering, Rutgers University, Piscataway, NJ, USA
5 shared publications Rohit Jindal
Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School; Shriners Hospitals for Children-Boston
5 shared publications
Latest Publications
- Open Access
- 29 September 2015
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 103,p. e53078
Layer-by-layer Collagen Deposition in Microfluidic Devices for Microtissue Stabilization
The creation of functional microtissues within microfluidic devices requires the stabilization of cell phenotypes by adapting...
- 29 September 2015
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 103,p. e53078
Open AccessLayer-by-layer Collagen Deposition in Microfluidic Devices for Microtissue Stabilization
The creation of functional microtissues within microfluidic devices requires the stabilization of cell phenotypes by adapting...
- 7 July 2015
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 113 (1) , 241-246
Long‐term maintenance of a microfluidic 3D human liver sinusoid
The development of long‐term human organotypic liver‐on‐a‐chip models for successful prediction of toxic response is one of the most important and urgent goals of the NIH/DARPA's initiative to replicate and replace chronic and acute drug testing in animals. For this purpose, we developed a microfluidic chip that consists of two microfluidic chambers separated by a porous membrane. The aim of this communication is to demonstrate the recapitulation of a liver sinusoid‐on‐a‐chip, using human cells only for a period of 28 days. Using a step‐by‐step method for building a 3D microtissue on‐a‐chip, we demonstrate that an organotypic in vitro model that reassembles the liver sinusoid microarchitecture can be maintained successfully for a period of 28 days. In addition, higher albumin synthesis (synthetic) and urea excretion (detoxification) were observed under flow compared to static cultures. This human liver‐on‐a‐chip should be further evaluated in drug‐related studies. Biotechnol. Bioeng. 2016;113: 241–246.
- 7 July 2015
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 113 (1) , 241-246
Long‐term maintenance of a microfluidic 3D human liver sinusoid
The development of long‐term human organotypic liver‐on‐a‐chip models for successful prediction of toxic response is one of the most important and urgent goals of the NIH/DARPA's initiative to replicate and replace chronic and acute drug testing in animals. For this purpose, we developed a microfluidic chip that consists of two microfluidic chambers separated by a porous membrane. The aim of this communication is to demonstrate the recapitulation of a liver sinusoid‐on‐a‐chip, using human cells only for a period of 28 days. Using a step‐by‐step method for building a 3D microtissue on‐a‐chip, we demonstrate that an organotypic in vitro model that reassembles the liver sinusoid microarchitecture can be maintained successfully for a period of 28 days. In addition, higher albumin synthesis (synthetic) and urea excretion (detoxification) were observed under flow compared to static cultures. This human liver‐on‐a‐chip should be further evaluated in drug‐related studies. Biotechnol. Bioeng. 2016;113: 241–246.
- 29 October 2014
- Published by SAGE Publications in Tissue Engineering Part C: Methods
- Vol. 21 (4) , 413-422
Long-Term Coculture Strategies for Primary Hepatocytes and Liver Sinusoidal Endothelial Cells
Hepatocytes and their in vitro models are essential tools for preclinical screening studies for drugs that affect the liver. Most of the current models primarily focus on hepatocytes alone and lack the contribution of non-parenchymal cells (NPCs), which are significant through both molecular and the response of the NPCs themselves. Models that incorporate NPCs alongside hepatocytes hold the power to enable more realistic recapitulation and elucidation of cell interactions and cumulative drug response. Hepatocytes and liver sinusoidal endothelial cells (LSECs) account for ∼80% of the liver mass where the LSECs line the walls of blood vessels, and act as a barrier between hepatocytes and blood. Culturing LSECs with hepatocytes to generate multicellular physiologically relevant in vitro liver models has been a major hurdle since LSECs lose their phenotype rapidly after isolation. To this end, we describe the application of collagen gel (1) in a sandwich and (2) as an intervening extracellular matrix layer to coculture hepatocytes with LSECs for extended periods. These coculture configurations provide environments wherein hepatocyte and LSECs, through cell–cell contacts and/or secretion factors, lead to enhanced function and stability of the cocultures. Our results show that in these configurations, hepatocytes and LSECs maintained their phenotypes when cultured together as a mixture, and showed stable secretion and metabolic activity for up to 4 weeks. Immunostaining for sinusoidal endothelial 1 (SE-1) antibody demonstrated retention of LSEC phenotype during the culture period. In addition, LSECs cultured alone maintained high viability and SE-1 expression when cultured within a collagen sandwich configuration up to 4 weeks. Albumin production of the cocultures was 10–15 times higher when LSECs were cultured as a bottom layer (with an intervening collagen layer) and as a mixture in a sandwich configuration, and native CYP 1A1/2 activity was at least 20 times higher than monoculture controls. Together, these data suggest that collagen gel-based hepatocyte-LSEC cocultures are highly suitable models for stabilization and long-term culture of both cell types. In summary, these results indicate that collagen gel-based hepatocyte-LSEC coculture models are promising for in vitro toxicity testing, and liver model development studies.
- 29 October 2014
- Published by SAGE Publications in Tissue Engineering Part C: Methods
- Vol. 21 (4) , 413-422
Long-Term Coculture Strategies for Primary Hepatocytes and Liver Sinusoidal Endothelial Cells
Hepatocytes and their in vitro models are essential tools for preclinical screening studies for drugs that affect the liver. Most of the current models primarily focus on hepatocytes alone and lack the contribution of non-parenchymal cells (NPCs), which are significant through both molecular and the response of the NPCs themselves. Models that incorporate NPCs alongside hepatocytes hold the power to enable more realistic recapitulation and elucidation of cell interactions and cumulative drug response. Hepatocytes and liver sinusoidal endothelial cells (LSECs) account for ∼80% of the liver mass where the LSECs line the walls of blood vessels, and act as a barrier between hepatocytes and blood. Culturing LSECs with hepatocytes to generate multicellular physiologically relevant in vitro liver models has been a major hurdle since LSECs lose their phenotype rapidly after isolation. To this end, we describe the application of collagen gel (1) in a sandwich and (2) as an intervening extracellular matrix layer to coculture hepatocytes with LSECs for extended periods. These coculture configurations provide environments wherein hepatocyte and LSECs, through cell–cell contacts and/or secretion factors, lead to enhanced function and stability of the cocultures. Our results show that in these configurations, hepatocytes and LSECs maintained their phenotypes when cultured together as a mixture, and showed stable secretion and metabolic activity for up to 4 weeks. Immunostaining for sinusoidal endothelial 1 (SE-1) antibody demonstrated retention of LSEC phenotype during the culture period. In addition, LSECs cultured alone maintained high viability and SE-1 expression when cultured within a collagen sandwich configuration up to 4 weeks. Albumin production of the cocultures was 10–15 times higher when LSECs were cultured as a bottom layer (with an intervening collagen layer) and as a mixture in a sandwich configuration, and native CYP 1A1/2 activity was at least 20 times higher than monoculture controls. Together, these data suggest that collagen gel-based hepatocyte-LSEC cocultures are highly suitable models for stabilization and long-term culture of both cell types. In summary, these results indicate that collagen gel-based hepatocyte-LSEC coculture models are promising for in vitro toxicity testing, and liver model development studies.
- Open Access
- 24 April 2014
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 239 (9) , 1180-1191
In vitroplatforms for evaluating liver toxicity
The liver is a heterogeneous organ with many vital functions, including metabolism of pharmaceutical drugs and is highly susceptible to injury from these substances. The etiology of drug-induced liver disease is still debated although generally regarded as a continuum between an activated immune response and hepatocyte metabolic dysfunction, most often resulting from an intermediate reactive metabolite. This debate stems from the fact that current animal and in vitro models provide limited physiologically relevant information, and their shortcomings have resulted in “silent” hepatotoxic drugs being introduced into clinical trials, garnering huge financial losses for drug companies through withdrawals and late stage clinical failures. As we advance our understanding into the molecular processes leading to liver injury, it is increasingly clear that (a) the pathologic lesion is not only due to liver parenchyma but is also due to the interactions between the hepatocytes and the resident liver immune cells, stellate cells, and endothelial cells; and (b) animal models do not reflect the human cell interactions. Therefore, a predictive human, in vitro model must address the interactions between the major human liver cell types and measure key determinants of injury such as the dosage and metabolism of the drug, the stress response, cholestatic effect, and the immune and fibrotic response. In this mini-review, we first discuss the current state of macro-scale in vitro liver culture systems with examples that have been commercialized. We then introduce the paradigm of microfluidic culture systems that aim to mimic the liver with physiologically relevant dimensions, cellular structure, perfusion, and mass transport by taking advantage of micro and nanofabrication technologies. We review the most prominent liver-on-a-chip platforms in terms of their physiological relevance and drug response. We conclude with a commentary on other critical advances such as the deployment of fluorescence-based biosensors to identify relevant toxicity pathways, as well as computational models to create a predictive tool.
- 24 April 2014
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 239 (9) , 1180-1191
Open AccessIn vitroplatforms for evaluating liver toxicity
The liver is a heterogeneous organ with many vital functions, including metabolism of pharmaceutical drugs and is highly susceptible to injury from these substances. The etiology of drug-induced liver disease is still debated although generally regarded as a continuum between an activated immune response and hepatocyte metabolic dysfunction, most often resulting from an intermediate reactive metabolite. This debate stems from the fact that current animal and in vitro models provide limited physiologically relevant information, and their shortcomings have resulted in “silent” hepatotoxic drugs being introduced into clinical trials, garnering huge financial losses for drug companies through withdrawals and late stage clinical failures. As we advance our understanding into the molecular processes leading to liver injury, it is increasingly clear that (a) the pathologic lesion is not only due to liver parenchyma but is also due to the interactions between the hepatocytes and the resident liver immune cells, stellate cells, and endothelial cells; and (b) animal models do not reflect the human cell interactions. Therefore, a predictive human, in vitro model must address the interactions between the major human liver cell types and measure key determinants of injury such as the dosage and metabolism of the drug, the stress response, cholestatic effect, and the immune and fibrotic response. In this mini-review, we first discuss the current state of macro-scale in vitro liver culture systems with examples that have been commercialized. We then introduce the paradigm of microfluidic culture systems that aim to mimic the liver with physiologically relevant dimensions, cellular structure, perfusion, and mass transport by taking advantage of micro and nanofabrication technologies. We review the most prominent liver-on-a-chip platforms in terms of their physiological relevance and drug response. We conclude with a commentary on other critical advances such as the deployment of fluorescence-based biosensors to identify relevant toxicity pathways, as well as computational models to create a predictive tool.
- 24 March 2014
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 14 (12) , 2033-2039
Dynamic interplay of flow and collagen stabilizes primary hepatocytes culture in a microfluidic platform
A two chambered device that enables sandwich culture of primary hepatocytes in conjunction with flow on top of the gel. Increased collagen secretion under flow leads to stabilization and enhancement of hepatocytes function
- 24 March 2014
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 14 (12) , 2033-2039
Dynamic interplay of flow and collagen stabilizes primary hepatocytes culture in a microfluidic platform
A two chambered device that enables sandwich culture of primary hepatocytes in conjunction with flow on top of the gel. Increased collagen secretion under flow leads to stabilization and enhancement of hepatocytes function
- Open Access
- 20 December 2013
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 4 (S1) , 1-6
Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans
Although the process of drug development requires efficacy and toxicity testing in animals prior to human testing, animal models have limited ability to accurately predict human responses to xenobiotics and other insults. Societal pressures are also focusing on reduction of and, ultimately, replacement of animal testing. However, a variety of in vitro models, explored over the last decade, have not been powerful enough to replace animal models. New initiatives sponsored by several US federal agencies seek to address this problem by funding the development of physiologically relevant human organ models on microscopic chips. The eventual goal is to simulate a human-on-a-chip, by interconnecting the organ models, thereby replacing animal testing in drug discovery and development. As part of this initiative, we aim to build a three-dimensional human liver chip that mimics the acinus, the smallest functional unit of the liver, including its oxygen gradient. Our liver-on-a-chip platform will deliver a microfluidic three-dimensional co-culture environment with stable synthetic and enzymatic function for at least 4 weeks. Sentinel cells that contain fluorescent biosensors will be integrated into the chip to provide multiplexed, real-time readouts of key liver functions and pathology. We are also developing a database to manage experimental data and harness external information to interpret the multimodal data and create a predictive platform.
- 20 December 2013
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 4 (S1) , 1-6
Open AccessTowards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans
Although the process of drug development requires efficacy and toxicity testing in animals prior to human testing, animal models have limited ability to accurately predict human responses to xenobiotics and other insults. Societal pressures are also focusing on reduction of and, ultimately, replacement of animal testing. However, a variety of in vitro models, explored over the last decade, have not been powerful enough to replace animal models. New initiatives sponsored by several US federal agencies seek to address this problem by funding the development of physiologically relevant human organ models on microscopic chips. The eventual goal is to simulate a human-on-a-chip, by interconnecting the organ models, thereby replacing animal testing in drug discovery and development. As part of this initiative, we aim to build a three-dimensional human liver chip that mimics the acinus, the smallest functional unit of the liver, including its oxygen gradient. Our liver-on-a-chip platform will deliver a microfluidic three-dimensional co-culture environment with stable synthetic and enzymatic function for at least 4 weeks. Sentinel cells that contain fluorescent biosensors will be integrated into the chip to provide multiplexed, real-time readouts of key liver functions and pathology. We are also developing a database to manage experimental data and harness external information to interpret the multimodal data and create a predictive platform.
- Open Access
- 29 August 2012
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (12) , 3993-4003
The biophysical mechanisms of altered hyaluronan concentration in synovial fluid after anterior cruciate ligament transection
Objective: The residence time of hyaluronan (HA) in knee joint synovial fluid (SF) was investigated using a rabbit anterior cruciate ligament transection (ACLT) model. The aims of this study were to assess, at 7 and 28 days after surgery, the 1) HA concentration and molecular mass (Mr) distribution in the SF, 2) endogenous replenishment of HA after saline washout, 3) HA residence times in the SF, and 4) synovium and subsynovium cellularity of the knee joints of rabbits subjected to ACLT, compared to sham‐operated and nonoperated control joints.Methods: Adult NZW rabbits underwent ACLT or sham surgery on one hind limb, while each contralateral limb was the nonoperated control. On day 7 or 28 after surgery, the joints were aspirated for SF, lavaged with saline, and injected with saline or polydisperse HA, and samples were obtained for analysis at set time points up to 8 hours after injection. Joint fluid samples were analyzed for the concentration andMrdistribution of HA to calculate the HA residence time constant.Results: Analysis of HA concentrations andMrdistributions showed 1) loss of high‐MrHA in the SF on day 7 and a shift toward a lower‐Mrdistribution on day 28, 2) endogenous replenishment of high‐MrHA after washout, and 3)Mr‐dependent loss of HA from the knee joints after ACLT, particularly on day 7 postsurgery. The HA residence time decreased with decreasing HAMr(residence time ∼27 hours with anMrload of 7,000–2,500 kd, to ∼7 hours with anMrload of 250–50 kd). HA residence time also decreased (by ∼70%) in the knee joints on day 7 after ACLT. The subsynovium of the joints subjected to ACLT displayed increased cellularity and neovascularization on days 7 and 28 postsurgery.Conclusion: The residence time of HA in the SF is transiently decreased after ACLT, suggesting that a biophysical transport mechanism is responsible for the altered composition of the SF after joint injury or during inflammation.
- 29 August 2012
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (12) , 3993-4003
Open AccessThe biophysical mechanisms of altered hyaluronan concentration in synovial fluid after anterior cruciate ligament transection
Objective: The residence time of hyaluronan (HA) in knee joint synovial fluid (SF) was investigated using a rabbit anterior cruciate ligament transection (ACLT) model. The aims of this study were to assess, at 7 and 28 days after surgery, the 1) HA concentration and molecular mass (Mr) distribution in the SF, 2) endogenous replenishment of HA after saline washout, 3) HA residence times in the SF, and 4) synovium and subsynovium cellularity of the knee joints of rabbits subjected to ACLT, compared to sham‐operated and nonoperated control joints.Methods: Adult NZW rabbits underwent ACLT or sham surgery on one hind limb, while each contralateral limb was the nonoperated control. On day 7 or 28 after surgery, the joints were aspirated for SF, lavaged with saline, and injected with saline or polydisperse HA, and samples were obtained for analysis at set time points up to 8 hours after injection. Joint fluid samples were analyzed for the concentration andMrdistribution of HA to calculate the HA residence time constant.Results: Analysis of HA concentrations andMrdistributions showed 1) loss of high‐MrHA in the SF on day 7 and a shift toward a lower‐Mrdistribution on day 28, 2) endogenous replenishment of high‐MrHA after washout, and 3)Mr‐dependent loss of HA from the knee joints after ACLT, particularly on day 7 postsurgery. The HA residence time decreased with decreasing HAMr(residence time ∼27 hours with anMrload of 7,000–2,500 kd, to ∼7 hours with anMrload of 250–50 kd). HA residence time also decreased (by ∼70%) in the knee joints on day 7 after ACLT. The subsynovium of the joints subjected to ACLT displayed increased cellularity and neovascularization on days 7 and 28 postsurgery.Conclusion: The residence time of HA in the SF is transiently decreased after ACLT, suggesting that a biophysical transport mechanism is responsible for the altered composition of the SF after joint injury or during inflammation.
- 1 November 2011
- Published by Elsevier in Journal of Biomechanics
- Vol. 44 (16) , 2761-2767
Fluid movement and joint capsule strains due to flexion in rabbit knees
- 1 November 2011
- Published by Elsevier in Journal of Biomechanics
- Vol. 44 (16) , 2761-2767
Fluid movement and joint capsule strains due to flexion in rabbit knees
- 8 August 2011
- Published by Wiley in WIREs Mechanisms of Disease
- Vol. 4 (1) , 15-37
A systems biology approach to synovial joint lubrication in health, injury, and disease
The synovial joint contains synovial fluid (SF) within a cavity bounded by articular cartilage and synovium. SF is a viscous fluid that has lubrication, metabolic, and regulatory functions within synovial joints. SF contains lubricant molecules, including proteoglycan‐4 and hyaluronan. SF is an ultrafiltrate of plasma with secreted contributions from cell populations lining and within the synovial joint space, including chondrocytes and synoviocytes. Maintenance of normal SF lubricant composition and function are important for joint homeostasis. In osteoarthritis, rheumatoid arthritis, and joint injury, changes in lubricant composition and function accompany alterations in the cytokine and growth factor environment and increased fluid and molecular transport through joint tissues. Thus, understanding the synovial joint lubrication system requires a multifaceted study of the various parts of the synovial joint and their interactions. Systems biology approaches at multiple scales are being used to describe the molecular, cellular, and tissue components and their interactions that comprise the functioning synovial joint. Analyses of the transcriptome and proteome of SF, cartilage, and synovium suggest that particular molecules and pathways play important roles in joint homeostasis and disease. Such information may be integrated with physicochemical tissue descriptions to construct integrative models of the synovial joint that ultimately may explain maintenance of health, recovery from injury, or development and progression of arthritis. WIREs Syst Biol Med 2012, 4:15–37. doi: 10.1002/wsbm.157This article is categorized under: Physiology > Mammalian Physiology in Health and Disease Translational, Genomic, and Systems Medicine > Translational Medicine
- 8 August 2011
- Published by Wiley in WIREs Mechanisms of Disease
- Vol. 4 (1) , 15-37
A systems biology approach to synovial joint lubrication in health, injury, and disease
The synovial joint contains synovial fluid (SF) within a cavity bounded by articular cartilage and synovium. SF is a viscous fluid that has lubrication, metabolic, and regulatory functions within synovial joints. SF contains lubricant molecules, including proteoglycan‐4 and hyaluronan. SF is an ultrafiltrate of plasma with secreted contributions from cell populations lining and within the synovial joint space, including chondrocytes and synoviocytes. Maintenance of normal SF lubricant composition and function are important for joint homeostasis. In osteoarthritis, rheumatoid arthritis, and joint injury, changes in lubricant composition and function accompany alterations in the cytokine and growth factor environment and increased fluid and molecular transport through joint tissues. Thus, understanding the synovial joint lubrication system requires a multifaceted study of the various parts of the synovial joint and their interactions. Systems biology approaches at multiple scales are being used to describe the molecular, cellular, and tissue components and their interactions that comprise the functioning synovial joint. Analyses of the transcriptome and proteome of SF, cartilage, and synovium suggest that particular molecules and pathways play important roles in joint homeostasis and disease. Such information may be integrated with physicochemical tissue descriptions to construct integrative models of the synovial joint that ultimately may explain maintenance of health, recovery from injury, or development and progression of arthritis. WIREs Syst Biol Med 2012, 4:15–37. doi: 10.1002/wsbm.157This article is categorized under: Physiology > Mammalian Physiology in Health and Disease Translational, Genomic, and Systems Medicine > Translational Medicine